Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Abemaciclib,CCN1CCN(CC1)CC1=CC=C(NC2=NC=C(F)C(=N2)C2=CC3=C(N=C(C)N3C(C)C)C(F)=C2)N=C1,Hepatic failure,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 208716/S-000 Part 09, page:24 PDF 678k",https://www.pharmapendium.com/browse/fda/Abemaciclib/a50315d3a726a8049e1d15f32cd253cf?reference=24,2017.0,CCN1CCN(CC1)CC1=CC=C(NC2=NC=C(F)C(=N2)C2=CC3=C(N=C(C)N3C(C)C)C(F)=C2)N=C1
Abiraterone Acetate,[H][C@@]12CC=C3C[C@H](CC[C@]3(C)[C@@]1([H])CC[C@]1(C)C(=CC[C@@]21[H])C1=CN=CC=C1)OC(C)=O,Hepatic failure,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 202379/S-005 Part 08, page:25 PDF 8941k",https://www.pharmapendium.com/browse/fda/Abiraterone Acetate/df9e8e13ef1657e4b4c8680206628198?reference=25,2012.0,[H][C]12CC=C3C[CH](CC[C]3(C)[C]1([H])CC[C]1(C)C(=CC[C]21[H])C1=CN=CC=C1)OC(C)=O
Acetazolamide Sodium,C\C([O-])=N\C1=NN=C(S1)S(N)(=O)=O,Hepatic failure,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 012945/S-037, S-038 Part 02, page:8 PDF 504k",https://www.pharmapendium.com/browse/fda/Acetazolamide Sodium/e5d463a87cd4eaec3059a7a016e6cf9b?reference=8,2005.0,C\C([O-])=N\C1=NN=C(S1)S(N)(=O)=O
Acitretin,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C,Hepatic failure,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 019821 Part 01, page:11 PDF 7773k",https://www.pharmapendium.com/browse/fda/Acitretin/1a0cb7a639fe6c5d73334f9d95bc1bc6?reference=11,1996.0,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C
Adefovir Dipivoxil,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C,Hepatic failure,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021449/S-000 Part 02, page:2 PDF 1758k",https://www.pharmapendium.com/browse/fda/Adefovir Dipivoxil/f59feb319af20abdd484a192c72a1024?reference=2,,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C
Agomelatine,COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1,Hepatic failure,Human,-1.3979400086720377,Repeated,Oral,"EMA approval document: ANNEX I, page:3 PDF 445k",https://www.pharmapendium.com/browse/ema/Agomelatine/8f1a8e32ead8fc917201fd71a0b5d214?reference=3,2020.0,COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1
Allopurinol Sodium,[O-]C1=NC=NC2=C1C=NN2,Hepatic failure,Human,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Medical Officer Review 020298, page:6 PDF 829k",https://www.pharmapendium.com/browse/fda/Allopurinol Sodium/5abae8ecd9a4c5e7111e7990c32914e5?reference=6,1993.0,[O-]C1=NC=NC2=C1C=NN2
Alprazolam,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,Hepatic failure,Human,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Printed Labeling 021726/S-000, page:19 PDF 1977k",https://www.pharmapendium.com/browse/fda/Alprazolam/1df31e0b37180d1cffaefc2ea15e6eca?reference=19,,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
Ambrisentan,COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatic failure,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 022081/S-017 Part 05, page:55 PDF 6131k",https://www.pharmapendium.com/browse/fda/Ambrisentan/7eb36e2aef104a107f4e978fef0262de?reference=55,2011.0,COC([CH](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1
Amphotericin B Liposome,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@H]([C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@H]1C)O2)C(O)=O,Hepatic failure,Human,-0.47712125471966244,Repeated,Intravenous,"FDA approval package document: Medical Officer Review 050740/S-000 Part 01, page:29 PDF 1551k",https://www.pharmapendium.com/browse/fda/Amphotericin B Liposome/19d5d0daddbe2dbdf5768428b0cd5659?reference=29,1997.0,C[CH]1OC(=O)C[CH](O)C[CH](O)CC[CH](O)[CH](O)C[CH](O)C[C]2(O)C[CH](O)[CH]([CH](C[CH](O[CH]3O[CH](C)[CH](O)[CH](N)[CH]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[CH](C)[CH](O)[CH]1C)O2)C(O)=O
Anidulafungin,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,Hepatic failure,Human,-0.6989700043360189,Repeated,Intravenous,"EMA approval document: ANNEX I, page:4 PDF 246k",https://www.pharmapendium.com/browse/ema/Anidulafungin/b0126dc536ecaaa2fca7659f1a5064c5?reference=4,2020.0,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[CH]1C[CH](O)[CH](O)NC(=O)[CH]2[CH](O)[CH](C)CN2C(=O)[CH](NC(=O)[CH](NC(=O)[CH]2C[CH](O)CN2C(=O)[CH](NC1=O)[CH](C)O)[CH](O)[CH](O)C1=CC=C(O)C=C1)[CH](C)O
Apixaban,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O,Hepatic failure,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202155/S-000 Part 21, page:7 PDF 4343k",https://www.pharmapendium.com/browse/fda/Apixaban/709e0370f29772b0b0d37de36ec49231?reference=7,2012.0,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
Argatroban,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=C2NCC(C)CC2=CC=C1,Hepatic failure,Human,-2.6989700043360187,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 020883/S-000 Part 02, page:16 PDF 1482k",https://www.pharmapendium.com/browse/fda/Argatroban/b122a5989d050ed712a3caf647e9286a?reference=16,2000.0,C[CH]1CCN([CH](C1)C(O)=O)C(=O)[CH](CCCNC(N)=N)NS(=O)(=O)C1=C2NCC(C)CC2=CC=C1
Aripiprazole,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl,Hepatic failure,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Approval Package 021436/S-019, S-020, S-022; 021713/S-014 Part 10, page:12 PDF 3580k",https://www.pharmapendium.com/browse/fda/Aripiprazole/de18cdf02f2dcd6fecbf15cd801fba12?reference=12,2008.0,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
Arsenic Trioxide,O1[As]2O[As]1O2,Hepatic failure,Human,-0.47712125471966244,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/CHMP/623089/2016; EMEA/H/C/000388/II/0058, page:49 PDF 2793k",https://www.pharmapendium.com/browse/ema/Arsenic Trioxide/fe610381fc16a4934c63adf8252ffd96?reference=49,2016.0,O1[As]2O[As]1O2
Atorvastatin Calcium,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,Hepatic failure,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Printed Labeling 077575/S-000, page:2 PDF 8877k",https://www.pharmapendium.com/browse/fda/Atorvastatin Calcium/b2b778f4f7c1d7393c50ff220ea5034f?reference=2,2010.0,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[CH](O)C[CH](O)CC([O-])=O)C1=CC=C(F)C=C1
Avapritinib,CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1,Hepatic failure,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/451735/2020; EMEA/H/C/005208/0000, page:113 PDF 6437k",https://www.pharmapendium.com/browse/ema/Avapritinib/a9be25284fcc55e1cf2294919763f338?reference=113,2020.0,CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C](C)(N)C3=CC=C(F)C=C3)C2=C1
Azithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,Hepatic failure,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Approval Package 065488/S-002 Part 01, page:14 PDF 2508k",https://www.pharmapendium.com/browse/fda/Azithromycin/6dbfdbc999ef9120663ed3d70f42ef80?reference=14,2017.0,CC[CH]1OC(=O)[CH](C)[CH](O[CH]2C[C](C)(OC)[CH](O)[CH](C)O2)[CH](C)[CH](O[CH]2O[CH](C)C[CH]([CH]2O)N(C)C)[C](C)(O)C[CH](C)CN(C)[CH](C)[CH](O)[C]1(C)O
Balsalazide Disodium,OC1=CC=C(C=C1C([O-])=O)\N=N\C1=CC=C(C=C1)C(=O)NCCC([O-])=O,Hepatic failure,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Label 022205/S-000, page:5 PDF 1039k",https://www.pharmapendium.com/browse/fda/Balsalazide Disodium/39f42c3ed4963ef1763049c817e6579c?reference=5,2012.0,OC1=CC=C(C=C1C([O-])=O)\N=N\C1=CC=C(C=C1)C(=O)NCCC([O-])=O
Benoxaprofen,CC(C(O)=O)C1=CC=C2OC(=NC2=C1)C1=CC=C(Cl)C=C1,Hepatic failure,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 018250 Part 05, page:92 PDF 8958k",https://www.pharmapendium.com/browse/fda/Benoxaprofen/4221dcac090aff247cd304eadbb31844?reference=92,1976.0,CC(C(O)=O)C1=CC=C2OC(=NC2=C1)C1=CC=C(Cl)C=C1
Bepridil Hydrochloride,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,Hepatic failure,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 019002 Part 01, page:35 PDF 3868k",https://www.pharmapendium.com/browse/fda/Bepridil Hydrochloride/de8e6fe6f954840cd41f1a0dbc1b255b?reference=35,1990.0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
Binimetinib,CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO,Hepatic failure,Human,-1.7781512503836436,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/CHMP/554701/2018; EMEA/H/C/004579/0000, page:161 PDF 7846k",https://www.pharmapendium.com/browse/ema/Binimetinib/7ff4ee13f77542f6f02b01b8fe161ec1?reference=161,2018.0,CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO
Bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1,Hepatic failure,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Label 209279/S-000, page:12 PDF 1644k",https://www.pharmapendium.com/browse/fda/Bosentan/648b177208c756f4b29e1bc828f06d66?reference=12,2017.0,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1
Bumetanide,CCCCNC1=CC(=CC(=C1OC1=CC=CC=C1)S(N)(=O)=O)C(O)=O,Hepatic failure,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Approval Package 018225/S-009, S-002; 018226/S-002 Part 02, page:58 PDF 6224k",https://www.pharmapendium.com/browse/fda/Bumetanide/52a32cff72a31c3a1e345079cd7f9bd7?reference=58,1981.0,CCCCNC1=CC(=CC(=C1OC1=CC=CC=C1)S(N)(=O)=O)C(O)=O
Buprenorphine Hydrochloride,[H][C@@]1(C[C@@]23CC[C@]1(OC)[C@@H]1OC4=C(O)C=CC5=C4[C@]21CCN(CC1CC1)[C@@H]3C5)[C@](C)(O)C(C)(C)C,Hepatic failure,Human,-1.2041199826559248,Repeated,Sublingual,"FDA approval package document: Medical/Clinical Review 204442/S-000 Part 06, page:137 PDF 22179k",https://www.pharmapendium.com/browse/fda/Buprenorphine Hydrochloride/f3b7b67010a881ad416f9c16b61b5110?reference=137,2013.0,[H][C]1(C[C]23CC[C]1(OC)[CH]1OC4=C(O)C=CC5=C4[C]21CCN(CC1CC1)[CH]3C5)[C](C)(O)C(C)(C)C
Carbamazepine,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,Hepatic failure,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 018281/S-031, page:16 PDF 2105k",https://www.pharmapendium.com/browse/fda/Carbamazepine/ce26ebd213d85fb7fb3989af05f689a3?reference=16,2001.0,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
Cefaclor,N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1,Hepatic failure,Human,-3.1760912590556813,Repeated,Oral,"FDA approval package document: Medical Officer Review 050673, page:22 PDF 823k",https://www.pharmapendium.com/browse/fda/Cefaclor/958552a37638588838bf75cc75ba80b6?reference=22,1993.0,N[CH](C(=O)N[CH]1[CH]2SCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
Cefdinir,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,Hepatic failure,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Printed Labeling 050749/S-000, page:23 PDF 1493k",https://www.pharmapendium.com/browse/fda/Cefdinir/10c4f05e362d284ea2ef7800cb8bc9b3?reference=23,1997.0,[H][C]12SCC(C=C)=C(N1C(=O)[CH]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O
Cefepime Hydrochloride,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1,Hepatic failure,Human,-3.3010299956639813,Repeated,Parenteral,"FDA approval package document: Approval Package 050679 Part 10, page:22 PDF 9169k",https://www.pharmapendium.com/browse/fda/Cefepime Hydrochloride/e11b724b8378a80dcad097995138d99f?reference=22,1996.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1
Cefmetazole Sodium,CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C([O-])=O,Hepatic failure,Human,-3.6020599913279625,Repeated,Parenteral,"FDA approval package document: Approval Package 050637 Part 04, page:52 PDF 6408k",https://www.pharmapendium.com/browse/fda/Cefmetazole Sodium/61867a5e5606504d9f1213d3ad346a7d?reference=52,1989.0,CO[C]1(NC(=O)CSCC#N)[CH]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C([O-])=O
Celecoxib,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,Hepatic failure,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020998/S-010 Part 01, page:30 PDF 1551k",https://www.pharmapendium.com/browse/fda/Celecoxib/f6ae2cf478c06c9128a40939d9a6a696?reference=30,2000.0,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
Ciprofloxacin Hydrochloride,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O,Hepatic failure,Human,-2.6020599913279625,Repeated,Intravenous,"FDA approval package document: Approval Package 019847/S-002, S-008, S-015; 019857/S-004, S-008, S-017; 019858/S-004, S-007, S-008, S-009, S-015 Part 11, page:20 PDF 7200k",https://www.pharmapendium.com/browse/fda/Ciprofloxacin Hydrochloride/dd6537ddafede0a5ba169663a935dd82?reference=20,1991.0,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O
Cladribine,NC1=NC(Cl)=NC2=C1N=CN2[C@@H]1C[C@H](O)[C@@H](CO)O1,Hepatic failure,Human,-0.9542425094393249,Repeated,Intravenous,"FDA approval package document: Approval Package 020229 Part 01, page:22 PDF 7054k",https://www.pharmapendium.com/browse/fda/Cladribine/9a965d8dbcda6fb2cf7389cad5f4e713?reference=22,1993.0,NC1=NC(Cl)=NC2=C1N=CN2[CH]1C[CH](O)[CH](CO)O1
Clobazam,CN1C(=O)CC(=O)N(C2=CC=CC=C2)C2=C1C=CC(Cl)=C2,Hepatic failure,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202067/S-000 Part 11, page:33 PDF 452k",https://www.pharmapendium.com/browse/fda/Clobazam/89f4ef88f01f7595fe2167ebdb1ee621?reference=33,2010.0,CN1C(=O)CC(=O)N(C2=CC=CC=C2)C2=C1C=CC(Cl)=C2
Clopidogrel Hydrobromide,COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C1=CC=CC=C1Cl,Hepatic failure,Human,-1.8750612633917,Repeated,Oral,"EMA approval document: ANNEX I, page:9 PDF 770k",https://www.pharmapendium.com/browse/ema/Clopidogrel Hydrobromide/f4e3980f774689c09aa0d0a34c5849df?reference=9,2015.0,COC(=O)[CH](N1CCC2=C(C1)C=CS2)C1=CC=CC=C1Cl
Clozapine,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2,Hepatic failure,Human,-2.9542425094393248,Repeated,Oral,"FDA approval package document: Label 203479/S-000, page:27 PDF 1267k",https://www.pharmapendium.com/browse/fda/Clozapine/107c277867a1040822f8ad90fa780b3d?reference=27,2013.0,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2
Conivaptan Hydrochloride,CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1,Hepatic failure,Human,-1.9030899869919435,Repeated,Oral/intravenous,"FDA approval package document: Medical/Clinical Review 021697/S-000 Part 01, page:74 PDF 5759k",https://www.pharmapendium.com/browse/fda/Conivaptan Hydrochloride/d4c3ea267d1e8379dd3867ad0fc78825?reference=74,2005.0,CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1
Crizotinib,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,Hepatic failure,Human,-2.3979400086720375,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/327604/2016; EMEA/H/C/002489/II/0039, page:53 PDF 2681k",https://www.pharmapendium.com/browse/ema/Crizotinib/6a9ab329e10da0bc09896710addd11ef?reference=53,2016.0,C[CH](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl
Cyclophosphamide,ClCCN(CCCl)P1(=O)NCCCO1,Hepatic failure,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Label 203856/S-000, page:7 PDF 333k",https://www.pharmapendium.com/browse/fda/Cyclophosphamide/d134b6b0c0f1d60144f6d82dbd25f9e9?reference=7,2013.0,ClCCN(CCCl)P1(=O)NCCCO1
Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,Hepatic failure,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 050573 Part 04, page:35 PDF 4409k",https://www.pharmapendium.com/browse/fda/Cyclosporine/6909d22756639b4844e9d9b997af0935?reference=35,1987.0,CC[CH]1NC(=O)[CH]([CH](O)[CH](C)C\C=C\C)N(C)C(=O)[CH](C(C)C)N(C)C(=O)[CH](CC(C)C)N(C)C(=O)[CH](CC(C)C)N(C)C(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CC(C)C)N(C)C(=O)[CH](NC(=O)[CH](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Daclatasvir Dihydrochloride,COC(=O)NC(C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)C(NC(=O)OC)C(C)C,Hepatic failure,Human,-1.7781512503836436,Repeated,Oral,"EMA approval document: Assessment Report EMA/419836/2014; EMEA/H/C/003768/0000, page:77 PDF 5506k",https://www.pharmapendium.com/browse/ema/Daclatasvir Dihydrochloride/209db9eedab6b5981bbf612f24b917ec?reference=77,2014.0,COC(=O)NC(C(C)C)C(=O)N1CCC[CH]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[CH]1CCCN1C(=O)C(NC(=O)OC)C(C)C
Dacomitinib,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,Hepatic failure,Human,-1.6532125137753437,Repeated,Oral,"EMA approval document: ANNEX I, page:6 PDF 337k",https://www.pharmapendium.com/browse/ema/Dacomitinib/1f9e16464dfeb7fd179b077eec8d7a0d?reference=6,2021.0,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Dasabuvir Sodium,COC1=C(C=C(C=C1C(C)(C)C)N1C=CC(=O)NC1=O)C1=CC=C2C=C([N-]S(C)(=O)=O)C=CC2=C1,Hepatic failure,Human,-2.3979400086720375,Repeated,Oral,"EMA approval document: ANNEX I, page:27 PDF 604k",https://www.pharmapendium.com/browse/ema/Dasabuvir Sodium/eeb87850fac098b7fb56dba3dd11b66b?reference=27,2017.0,COC1=C(C=C(C=C1C(C)(C)C)N1C=CC(=O)NC1=O)C1=CC=C2C=C([N-]S(C)(=O)=O)C=CC2=C1
Deferasirox,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O,Hepatic failure,Human,-1.1760912590556813,Repeated,Oral,"EMA approval document: Assessment Report EMA/44672/2013; EMEA/H/C/000670/II/0026, page:34 PDF 3055k",https://www.pharmapendium.com/browse/ema/Deferasirox/a8f20b38c6e6b768ecfb72bbf27f7278?reference=34,2012.0,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Deferiprone,CN1C=CC(=O)C(O)=C1C,Hepatic failure,Human,-1.8750612633917,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021825/S-000 Part 14, page:7 PDF 847k",https://www.pharmapendium.com/browse/fda/Deferiprone/2f6570a61c376aecdf77d49b471f2ec3?reference=7,2011.0,CN1C=CC(=O)C(O)=C1C
Dexamethasone,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Hepatic failure,Human,-2.845098040014257,Repeated,Ocular,"FDA approval package document: Approval Package 022315/S-009 Part 11, page:32 PDF 615k",https://www.pharmapendium.com/browse/fda/Dexamethasone/cda53a0584b3cf01ecbc765a1e3dfbba?reference=32,2014.0,[H][C]12C[CH](C)[C](O)(C(=O)CO)[C]1(C)C[CH](O)[C]1(F)[C]2([H])CCC2=CC(=O)C=C[C]12C
Diclofenac,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Hepatic failure,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Approval Package 204592/S-002 Part 04, page:97 PDF 18140k",https://www.pharmapendium.com/browse/fda/Diclofenac/5fad2614920d8af878670ad356415995?reference=97,2014.0,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Diclofenac Potassium,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Hepatic failure,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Label 022165/S-000, page:5 PDF 1056k",https://www.pharmapendium.com/browse/fda/Diclofenac Potassium/bee628ad74512445c9862588c833927f?reference=5,2009.0,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Dolutegravir Sodium,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,Hepatic failure,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204790 Part 04, page:12 PDF 7848k",https://www.pharmapendium.com/browse/fda/Dolutegravir Sodium/1ad0a2b9727ce58261902f144c3cb335?reference=12,2012.0,[H][C]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[CH](C)CCO2
Doravirine,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F,Hepatic failure,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 210806/S-000 Part 06, page:38 PDF 11051k",https://www.pharmapendium.com/browse/fda/Doravirine/7babb97ed6a4ea205e52af3956344af6?reference=38,2018.0,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F
Dronedarone Hydrochloride,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,Hepatic failure,Human,-2.9030899869919438,Repeated,Intramuscular,"EMA approval document: Assessment Report EMEA/H/C/1043/A20/005, page:19 PDF 943k",https://www.pharmapendium.com/browse/ema/Dronedarone Hydrochloride/ac8f06b056b2958a2f0f1a402458ce78?reference=19,2011.0,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12
Duloxetine Hydrochloride,CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1,Hepatic failure,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 021427/S-039 Part 03, page:3 PDF 377k",https://www.pharmapendium.com/browse/fda/Duloxetine Hydrochloride/0ac4e3a6151ac4f052501244685e01ea?reference=3,2011.0,CNCC[CH](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1
Efavirenz,FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1,Hepatic failure,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: ANNEX I, page:21 PDF 427k",https://www.pharmapendium.com/browse/ema/Efavirenz/313ece5412a4e58600752180aa3a62b0?reference=21,2019.0,FC(F)(F)[C]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1
Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1,Hepatic failure,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 204629/S-001, S-002, S-003 Part 02, page:20 PDF 4874k",https://www.pharmapendium.com/browse/fda/Empagliflozin/d9389650199146fc07985b7833daf787?reference=20,2015.0,OC[CH]1O[CH]([CH](O)[CH](O)[CH]1O)C1=CC(CC2=CC=C(O[CH]3CCOC3)C=C2)=C(Cl)C=C1
Encorafenib,COC(=O)N[C@@H](C)CNC1=NC=CC(=N1)C1=CN(N=C1C1=C(F)C(NS(C)(=O)=O)=CC(Cl)=C1)C(C)C,Hepatic failure,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/271532/2020; EMEA/H/C/xxxx/WS/1695, page:212 PDF 15594k",https://www.pharmapendium.com/browse/ema/Encorafenib/8c8f4d082a6f7118ffe9c0eae4208fd6?reference=212,2020.0,COC(=O)N[CH](C)CNC1=NC=CC(=N1)C1=CN(N=C1C1=C(F)C(NS(C)(=O)=O)=CC(Cl)=C1)C(C)C
Enfuvirtide,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,Hepatic failure,Human,-1.954242509439325,Repeated,Subcutaneous,"FDA approval package document: Medical/Clinical Review 021481/S-000 Part 02, page:33 PDF 1536k",https://www.pharmapendium.com/browse/fda/Enfuvirtide/13be3f6c3927e2064d59f5fb1f99a916?reference=33,2003.0,CC[CH](C)[CH](NC(=O)[CH](CC(C)C)NC(=O)[CH](CO)NC(=O)[CH](CC1=CNC=N1)NC(=O)[CH](NC(=O)[CH](CC(C)C)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=C(O)C=C1)NC(C)=O)[CH](C)O)[CH](C)CC)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CO)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CCCCN)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC(O)=O)C(=O)N[CH](CCCCN)C(=O)N[CH](CC1=CNC2=CC=CC=C12)C(=O)N[CH](C)C(=O)N[CH](CO)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC1=CNC2=CC=CC=C12)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CC1=CNC2=CC=CC=C12)C(=O)N[CH](CC1=CC=CC=C1)C(N)=O
Enzalutamide,CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC(=C(C=C1)C#N)C(F)(F)F,Hepatic failure,Human,-2.2041199826559246,Repeated,Oral,"EMA approval document: Assessment Report EMA/41918/2019; EMEA/H/C/002639/II/0039/G, page:71 PDF 4229k",https://www.pharmapendium.com/browse/ema/Enzalutamide/8a68b323214cba48be01f6c2b08c5cec?reference=71,2018.0,CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC(=C(C=C1)C#N)C(F)(F)F
Erlotinib Hydrochloride,COCCOC1=CC2=NC=NC(NC3=CC=CC(=C3)C#C)=C2C=C1OCCOC,Hepatic failure,Human,-2.1760912590556813,Repeated,Oral,"EMA approval document: ANNEX I, page:5 PDF 558k",https://www.pharmapendium.com/browse/ema/Erlotinib Hydrochloride/897dc79c5db058f0a3b2dcaa2d959966?reference=5,2019.0,COCCOC1=CC2=NC=NC(NC3=CC=CC(=C3)C#C)=C2C=C1OCCOC
Eslicarbazepine Acetate,CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2,Hepatic failure,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022416/S-000 Part 17, page:9 PDF 453k",https://www.pharmapendium.com/browse/fda/Eslicarbazepine Acetate/459bd37af93f1fbbbf90e8b0afb596ac?reference=9,2013.0,CC(=O)O[CH]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2
Esomeprazole Magnesium,COC1=CC=C2[N-]C(=NC2=C1)[S@@](=O)CC1=NC=C(C)C(OC)=C1C,Hepatic failure,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204655/S-000 Part 06, page:32 PDF 6035k",https://www.pharmapendium.com/browse/fda/Esomeprazole Magnesium/afdd7c58859f0f4165b2c56079a95642?reference=32,2013.0,COC1=CC=C2[N-]C(=NC2=C1)[S](=O)CC1=NC=C(C)C(OC)=C1C
Esomeprazole Sodium,COC1=CC2=C([N-]C(=N2)S(=O)CC2=C(C)C(OC)=C(C)C=N2)C=C1,Hepatic failure,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Label 021689/S-007, page:9 PDF 284k",https://www.pharmapendium.com/browse/fda/Esomeprazole Sodium/1c22435c698e9787f474311d5feda16d?reference=9,2006.0,COC1=CC2=C([N-]C(=N2)S(=O)CC2=C(C)C(OC)=C(C)C=N2)C=C1
Etodolac,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O,Hepatic failure,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 018922/S-007, S-008, S-013, S-014, S-015 Part 26, page:19 PDF 6654k",https://www.pharmapendium.com/browse/fda/Etodolac/cf790bf1f865041d2f2acca39e9be5e3?reference=19,1991.0,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O
Etravirine,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N,Hepatic failure,Human,-2.3010299956639813,Repeated,Oral,Reference from PharmaPendium Published Toxicity: etravirine_tcrm-6-049   ---   JOURNAL:Therapeutics and Clinical Risk Management   PAGES:49   VOLUME:6,,2010.0,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
Etretinate,CCOC(=O)\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)C(C)=C(OC)C=C1C,Hepatic failure,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 019369/S-000, page:43 PDF 4059k",https://www.pharmapendium.com/browse/fda/Etretinate/4c025033beb9f3519d74d667b534ae21?reference=43,1986.0,CCOC(=O)\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)C(C)=C(OC)C=C1C
Everolimus,CO[C@@H]1C[C@@H](CC[C@H]1OCCO)C[C@@H](C)[C@@H]1CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1)OC,Hepatic failure,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 022334/S-016 Part 01, page:21 PDF 606k",https://www.pharmapendium.com/browse/fda/Everolimus/66a722b758fec7a207264b476d5c96c1?reference=21,2012.0,CO[CH]1C[CH](CC[CH]1OCCO)C[CH](C)[CH]1CC(=O)[CH](C)\C=C(C)\[CH](O)[CH](OC)C(=O)[CH](C)C[CH](C)\C=C\C=C\C=C(C)\[CH](C[CH]2CC[CH](C)[C](O)(O2)C(=O)C(=O)N2CCCC[CH]2C(=O)O1)OC
Exemestane,[H][C@@]12CC(=C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)C(=O)CC[C@@]21[H],Hepatic failure,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020753/S-000 Part 01, page:3 PDF 1606k",https://www.pharmapendium.com/browse/fda/Exemestane/1d9946053261da4c16789f9941a55f66?reference=3,1999.0,[H][C]12CC(=C)C3=CC(=O)C=C[C]3(C)[C]1([H])CC[C]1(C)C(=O)CC[C]21[H]
Famotidine,N\C(N)=N/C1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1,Hepatic failure,Human,-0.0,Repeated,Oral,"FDA approval package document: Approval Package 020752/S-005; 019527/S-024; 019462/S-030, page:59 PDF 6534k",https://www.pharmapendium.com/browse/fda/Famotidine/90f64d44c3867c64c3a853f5536ea5a9?reference=59,2002.0,N\C(N)=N/C1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
Fexofenadine Hydrochloride,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatic failure,Human,-2.5563025007672873,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201373/S-000 Part 01, page:19 PDF 743k",https://www.pharmapendium.com/browse/fda/Fexofenadine Hydrochloride/7282c9edf57b7af5577d3d55b966b526?reference=19,2010.0,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Fingolimod Hydrochloride,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,Hepatic failure,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022527/S-000 Part 05, page:53 PDF 786k",https://www.pharmapendium.com/browse/fda/Fingolimod Hydrochloride/c8b53d0c6a59022551398819a38f2a25?reference=53,2009.0,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
Fluoxetine Hydrochloride,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,Hepatic failure,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Label 021427/S-012; 021520/S-011; 021235/S-007; 020974/S-008; 020101/S-035; 018936/S-076, page:26 PDF 964k",https://www.pharmapendium.com/browse/fda/Fluoxetine Hydrochloride/3b69d8bbe852a64df615fb05309f07c6?reference=26,2006.0,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Flurbiprofen,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1,Hepatic failure,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Label 018766/S-013, page:11 PDF 339k",https://www.pharmapendium.com/browse/fda/Flurbiprofen/42077615ee502ab6ea0ace4341e5e783?reference=11,2006.0,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
Fluvastatin Sodium,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O,Hepatic failure,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 020261/S-046 Part 01, page:16 PDF 766k",https://www.pharmapendium.com/browse/fda/Fluvastatin Sodium/6637ae45ed8c4ae449132be247b558f3?reference=16,2012.0,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[CH](O)C[CH](O)CC([O-])=O
Fulvestrant,[H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=C2C=CC(O)=C1,Hepatic failure,Human,-2.6989700043360187,Repeated,Intramuscular,"EMA approval document: Assessment Report EMA/53381/2018; EMEA/H/C/000540/II/0059, page:41 PDF 2093k",https://www.pharmapendium.com/browse/ema/Fulvestrant/9afb5e89d365a23b84a529340383ed87?reference=41,2017.0,[H][C]12CC[C]3(C)[CH](O)CC[C]3([H])[C]1([H])[CH](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1=C2C=CC(O)=C1
Ganciclovir Sodium,NC1=NC2=C(N=CN2COC(CO)CO)C([O-])=N1,Hepatic failure,Human,-3.4771212547196626,Repeated,Oral,"FDA approval package document: Label 019661/S-030, page:20 PDF 690k",https://www.pharmapendium.com/browse/fda/Ganciclovir Sodium/0078e0911648eae74c95fa905199c725?reference=20,2006.0,NC1=NC2=C(N=CN2COC(CO)CO)C([O-])=N1
Gefitinib,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC(Cl)=C(F)C=C1)=NC=N2,Hepatic failure,Human,-2.3979400086720375,Repeated,Oral,"EMA approval document: ANNEX I, page:4 PDF 311k",https://www.pharmapendium.com/browse/ema/Gefitinib/20d5f23f58100a5577a39e215510e76c?reference=4,2019.0,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC(Cl)=C(F)C=C1)=NC=N2
Glimepiride,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O,Hepatic failure,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Label 020496/S-015, page:10 PDF 279k",https://www.pharmapendium.com/browse/fda/Glimepiride/78c66922e53dc9a8e6ff87e31f73c73f?reference=10,2005.0,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[CH]2CC[CH](C)CC2)C1=O
Hydromorphone Hydrochloride,[H][C@]12CCC(=O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4O,Hepatic failure,Human,-1.806179973983887,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021217/S-000 Part 03, page:11 PDF 1765k",https://www.pharmapendium.com/browse/fda/Hydromorphone Hydrochloride/03f35435dfac7c0b0444e814c95540b4?reference=11,2009.0,[H][C]12CCC(=O)[CH]3OC4=C5C(C[CH]1N(C)CC[C]235)=CC=C4O
Ibrutinib,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,Hepatic failure,Human,-2.7481880270062002,Repeated,Oral,"EMA approval document: Other Information from EMA, page:5 PDF 119k",https://www.pharmapendium.com/browse/ema/Ibrutinib/cd0c850002fc9f92bc5d50c799bf73b3?reference=5,2020.0,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[CH]1CCCN(C1)C(=O)C=C
Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,Hepatic failure,Human,-3.505149978319906,Repeated,Oral,"FDA approval package document: Approval Package 020418 Part 03, page:22 PDF 7533k",https://www.pharmapendium.com/browse/fda/Ibuprofen/5a1a31ad58014ee8268af0464c1e763c?reference=22,1994.0,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Idelalisib,CC[C@H](NC1=C2N=CNC2=NC=N1)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1,Hepatic failure,Human,-2.1760912590556813,Repeated,Oral,"EMA approval document: Other Information from EMA, page:3 PDF 256k",https://www.pharmapendium.com/browse/ema/Idelalisib/3216135fba00cc76e36d3fb7854bffe6?reference=3,2020.0,CC[CH](NC1=C2N=CNC2=NC=N1)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1
Indomethacin,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,Hepatic failure,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Label 204768/S-000, page:24 PDF 513k",https://www.pharmapendium.com/browse/fda/Indomethacin/8739319fb80bf8712b81706fd68b8752?reference=24,2014.0,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,Hepatic failure,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Label 022484/S-000, page:4 PDF 424k",https://www.pharmapendium.com/browse/fda/Itraconazole/3cd8b4a77b6097a6d0ac27f3d8906782?reference=4,2010.0,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,Hepatic failure,Human,-3.0791812460476247,Repeated,Oral,"EMA approval document: ANNEX I, page:16 PDF 553k",https://www.pharmapendium.com/browse/ema/Ketoconazole/8d2315e4697688e9c94ee9b957e597c1?reference=16,2020.0,[H][C]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl
Ketoprofen,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1,Hepatic failure,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical Officer Review 020429 Part 02, page:24 PDF 1711k",https://www.pharmapendium.com/browse/fda/Ketoprofen/294fff90244c022796a65f8836bc24b2?reference=24,1995.0,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
Lamivudine,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1,Hepatic failure,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021003/S-000; 021004/S-000 Part 02, page:9 PDF 1190k",https://www.pharmapendium.com/browse/fda/Lamivudine/7c6e1619f95c9fc2e29616fe111898a9?reference=9,1998.0,NC1=NC(=O)N(C=C1)[CH]1CS[CH](CO)O1
Lamotrigine,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl,Hepatic failure,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 022115/S-006 Part 05, page:120 PDF 19220k",https://www.pharmapendium.com/browse/fda/Lamotrigine/bec809595ceba0896a61b27b477d09cb?reference=120,2011.0,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl
Leflunomide,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Hepatic failure,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/478482/2013; EMEA/H/C/001227/X/0012/G, page:17 PDF 243k",https://www.pharmapendium.com/browse/ema/Leflunomide/8c5ee593d87230d2f1e5fca39db1ea67?reference=17,2013.0,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Hepatic failure,Human,-1.3979400086720377,Repeated,Oral,"EMA approval document: ANNEX I, page:20 PDF 864k",https://www.pharmapendium.com/browse/ema/Lenalidomide/796402210a489a77aef74fc2ff3342af?reference=20,2021.0,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,Hepatic failure,Human,-3.1760912590556813,Repeated,Oral,"EMA approval document: ANNEX I, page:10 PDF 306k",https://www.pharmapendium.com/browse/ema/Levetiracetam/9874c62cce3ca8764edf55cf95c560fb?reference=10,2020.0,CC[CH](N1CCCC1=O)C(N)=O
Levocarnitine,C[N+](C)(C)C[C@H](O)CC([O-])=O,Hepatic failure,Human,-3.4727564493172123,Repeated,Oral,"FDA approval package document: Approval Package 018948/S-017, S-009, S-004, S-016 Part 03, page:9 PDF 4713k",https://www.pharmapendium.com/browse/fda/Levocarnitine/ae3e3b8ec4f682719affe2e719743cc3?reference=9,1995.0,C[N+](C)(C)C[CH](O)CC([O-])=O
Levofloxacin,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Hepatic failure,Human,-2.8750612633917,Repeated,Oral,"FDA approval package document: Approval Package 020634/S-028; 020635/S-027 Part 01, page:32 PDF 6823k",https://www.pharmapendium.com/browse/fda/Levofloxacin/fde9c2ebdefc64354e914d50d204a952?reference=32,2003.0,C[CH]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,Hepatic failure,Human,-0.9030899869919435,Repeated,Subcutaneous,"FDA approval package document: Approval Package 022341/S-027 Part 33, page:4 PDF 1470k",https://www.pharmapendium.com/browse/fda/Liraglutide/eabaa71151623fbf6b0c46815dfb24fa?reference=4,2016.0,CCCCCCCCCCCCCCCC(=O)N[CH](CCC(=O)NCCCC[CH](NC(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CCC(N)=O)NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC1=CC=C(O)C=C1)NC(=O)[CH](CO)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=CC=C1)NC(=O)[CH](NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](C)NC(=O)[CH](N)CC1=CN=CN1)[CH](C)O)[CH](C)O)C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CC=CC=C1)C(=O)N[CH]([CH](C)CC)C(=O)N[CH](C)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)NCC(=O)N[CH](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
Lisinopril,[H][C@]1(CCCN1C(=O)[C@H](CCCCN)N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(O)=O,Hepatic failure,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 019777/S-007, S-010, S-014, S-016, S-019, S-021, S-022, S-023, S-024, S-025; 019888/S-007, S-009, S-014, S-021; 019558 Part 18, page:6 PDF 3928k",https://www.pharmapendium.com/browse/fda/Lisinopril/5065f703a5236d6af5315bf1cf7784d4?reference=6,1988.0,[H][C]1(CCCN1C(=O)[CH](CCCCN)N[CH](CCC1=CC=CC=C1)C(O)=O)C(O)=O
Loratadine,CCOC(=O)N1CC\C(CC1)=C1\C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,Hepatic failure,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021512/S-000, page:47 PDF 5129k",https://www.pharmapendium.com/browse/fda/Loratadine/689b662fc01741a2528c703f19e17543?reference=47,2004.0,CCOC(=O)N1CC\C(CC1)=C1\C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2
Lovastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,Hepatic failure,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 019643/S-085 Part 01, page:20 PDF 889k",https://www.pharmapendium.com/browse/fda/Lovastatin/49df1f2def59b577a26da033399dbff1?reference=20,2012.0,[H][C]12[CH](C[CH](C)C=C1C=C[CH](C)[CH]2CC[CH]1C[CH](O)CC(=O)O1)OC(=O)[CH](C)CC
Maraviroc,[H][C@]12CC[C@]([H])(C[C@H](C1)N1C(C)=NN=C1C(C)C)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1,Hepatic failure,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: ANNEX I, page:16 PDF 775k",https://www.pharmapendium.com/browse/ema/Maraviroc/c4b566d7660838911f6e544f697ed177?reference=16,2020.0,[H][C]12CC[C]([H])(C[CH](C1)N1C(C)=NN=C1C(C)C)N2CC[CH](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Meloxicam,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O,Hepatic failure,Human,-1.1760912590556813,Repeated,Oral,"FDA approval package document: Printed Labeling 020938, page:14 PDF 586k",https://www.pharmapendium.com/browse/fda/Meloxicam/1a6d50b6469890b803fae81cf0e92b31?reference=14,,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O
Memantine Hydrochloride,[H][C@]12C[C@]3(C)C[C@](C)(C1)C[C@](N)(C2)C3,Hepatic failure,Human,-1.4471580313422192,Repeated,Oral,"FDA approval package document: Label 022525/S-000, page:8 PDF 368k",https://www.pharmapendium.com/browse/fda/Memantine Hydrochloride/456f9296816fa8a789fea898abe00faa?reference=8,2010.0,[H][C]12C[C]3(C)C[C](C)(C1)C[C](N)(C2)C3
Mesalamine,NC1=CC(C(O)=O)=C(O)C=C1,Hepatic failure,Human,-3.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022301/S-000 Part 01, page:9 PDF 6658k",https://www.pharmapendium.com/browse/fda/Mesalamine/bd27fc9deb3575b96265dbabfa9b40fb?reference=9,2008.0,NC1=CC(C(O)=O)=C(O)C=C1
Metaxalone,CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1,Hepatic failure,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022503/S-000 Part 03, page:4 PDF 916k",https://www.pharmapendium.com/browse/fda/Metaxalone/a392c7d696933c4ca7578b1b6565aa1c?reference=4,2010.0,CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1
Micafungin Sodium,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[C@H](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O,Hepatic failure,Human,-0.9030899869919435,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/494096/2019; EMEA/H/C/000734/P46/040, page:18 PDF 703k",https://www.pharmapendium.com/browse/ema/Micafungin Sodium/e6e1c6e5d06ae34193962ebee1fca0ac?reference=18,2019.0,[H][C]12C[CH](O)CN1C(=O)[CH](NC(=O)[CH](C[CH](O)[CH](O)NC(=O)[C]1([H])[CH](O)[CH](C)CN1C(=O)[CH](NC(=O)[CH](NC2=O)[CH](O)[CH](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[CH](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[CH](C)O
Minocycline Hydrochloride,[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,Hepatic failure,Human,-0.0,Repeated,Oral,"FDA approval package document: Approval Package 050808/S-014 Part 01, page:10 PDF 303k",https://www.pharmapendium.com/browse/fda/Minocycline Hydrochloride/31f5da0487309d3b69b91cef30181e69?reference=10,2011.0,[H][C]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])C2
Moxifloxacin Hydrochloride,[H][C@@]12CCCN[C@]1([H])CN(C2)C1=C(OC)C2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O,Hepatic failure,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021085/S-010; 021334/S-000, page:42 PDF 1745k",https://www.pharmapendium.com/browse/fda/Moxifloxacin Hydrochloride/1662ebfc721a7169705e8138fce783a5?reference=42,2001.0,[H][C]12CCCN[C]1([H])CN(C2)C1=C(OC)C2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O
Nebivolol Hydrochloride,[H][C@@]1(CCC2=CC(F)=CC=C2O1)[C@H](O)CNC[C@@H](O)[C@]1([H])CCC2=CC(F)=CC=C2O1,Hepatic failure,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021742/S-000 Part 07, page:63 PDF 5831k",https://www.pharmapendium.com/browse/fda/Nebivolol Hydrochloride/c22a1b61a9df4fdde7d3660c5a0ba709?reference=63,2007.0,[H][C]1(CCC2=CC(F)=CC=C2O1)[CH](O)CNC[CH](O)[C]1([H])CCC2=CC(F)=CC=C2O1
Nevirapine,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1,Hepatic failure,Human,-2.3010299956639813,Repeated,Oral,"EMA approval document: Scientific Discussion, page:20 PDF 291k",https://www.pharmapendium.com/browse/ema/Nevirapine/36844ab8bce64b41f0622a330ee85655?reference=20,2004.0,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1
Nilotinib Hydrochloride Monohydrate,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F,Hepatic failure,Human,-2.9030899869919438,Repeated,Oral,"EMA approval document: Assessment Report EMA/313746/2017; EMEA/H/C/000798/II/0084/G, page:65 PDF 2138k",https://www.pharmapendium.com/browse/ema/Nilotinib Hydrochloride Monohydrate/d01e77935612f8a2f5c9961a577b6a3b?reference=65,2017.0,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F
Nitisinone,FC(F)(F)C1=CC=C(C(=O)C2C(=O)CCCC2=O)C(=C1)N(=O)=O,Hepatic failure,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: Scientific Discussion, page:23 PDF 329k",https://www.pharmapendium.com/browse/ema/Nitisinone/0c62cb3e775fc7a38d518fdb19f3281d?reference=23,2005.0,FC(F)(F)C1=CC=C(C(=O)C2C(=O)CCCC2=O)C(=C1)N(=O)=O
Nizatidine,CN\C(NCCSCC1=CSC(CN(C)C)=N1)=C\N(=O)=O,Hepatic failure,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 020555/S-003, S-004, page:39 PDF 1268k",https://www.pharmapendium.com/browse/fda/Nizatidine/57d1a1c346b6bf8b3984387b1617c75c?reference=39,,CN\C(NCCSCC1=CSC(CN(C)C)=N1)=C\N(=O)=O
Obeticholic Acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,Hepatic failure,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207999/S-000 Part 04, page:76 PDF 18785k",https://www.pharmapendium.com/browse/fda/Obeticholic Acid/fd9575acfa8e5dadbfa0aa39e5adfd26?reference=76,2016.0,[H][C]1(CC[C]2([H])[C]3([H])[CH](O)[CH](CC)[C]4([H])C[CH](O)CC[C]4(C)[C]3([H])CC[C]12C)[CH](C)CCC(O)=O
Omeprazole,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Hepatic failure,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 019810/S-002, S-007, S-036, S-037, S-009, S-010, S-022, S-035, S-019, S-023, S-025, S-033, S-034; 050662/S-010 Part 21, page:42 PDF 6127k",https://www.pharmapendium.com/browse/fda/Omeprazole/1f18354d13e32eec8cbbb691e34fed35?reference=42,1990.0,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Omeprazole Magnesium,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Hepatic failure,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021229/S-000, page:365 PDF 20401k",https://www.pharmapendium.com/browse/fda/Omeprazole Magnesium/42ffe48b5d32d8a231f5c085c007aa78?reference=365,2003.0,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Ondansetron,CN1C2=C(C(=O)C(CC2)CN2C=CN=C2C)C2=C1C=CC=C2,Hepatic failure,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Label 020781/S-010; 020605/S-010; 020103/S-027, page:8 PDF 348k",https://www.pharmapendium.com/browse/fda/Ondansetron/94c52cbe29cb0692bedae8a25ebb1bd0?reference=8,2006.0,CN1C2=C(C(=O)C(CC2)CN2C=CN=C2C)C2=C1C=CC=C2
Orlistat,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,Hepatic failure,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021887/S-000 Part 01, page:49 PDF 4480k",https://www.pharmapendium.com/browse/fda/Orlistat/3f97e8190e694a8cb2e2e90a1f1afa61?reference=49,2005.0,CCCCCCCCCCC[CH](C[CH]1OC(=O)[CH]1CCCCCC)OC(=O)[CH](CC(C)C)NC=O
Oxcarbazepine,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12,Hepatic failure,Human,-3.5563025007672873,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021014/S-000 Part 06, page:28 PDF 1647k",https://www.pharmapendium.com/browse/fda/Oxcarbazepine/44b120c1ccabb76ebd73a0eb1292f6c2?reference=28,1999.0,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12
Oxymetholone,[H][C@@]12CC[C@]3([H])[C@]([H])(CC[C@@]4(C)[C@@]3([H])CC[C@]4(C)O)[C@@]1(C)C\C(C(=O)C2)=C/O,Hepatic failure,Human,-1.6989700043360187,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Oxymetholone353   ---   DOI:10.1182/blood.v40.3.353.353   JOURNAL:Blood   PAGES:353   VOLUME:40,http://dx.doi.org/10.1182/blood.v40.3.353.353,1972.0,[H][C]12CC[C]3([H])[C]([H])(CC[C]4(C)[C]3([H])CC[C]4(C)O)[C]1(C)C\C(C(=O)C2)=C/O
Pantoprazole Sodium,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1,Hepatic failure,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020987/S-007, page:34 PDF 1373k",https://www.pharmapendium.com/browse/fda/Pantoprazole Sodium/fc792609ea1639d725d409fa83f0f250?reference=34,2002.0,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1
Pazopanib Hydrochloride,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1,Hepatic failure,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022465/S-000, page:57 PDF 1560k",https://www.pharmapendium.com/browse/fda/Pazopanib Hydrochloride/893f6f8879191ff31ae434f60b8e4e98?reference=57,2009.0,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1
Pemoline,N=C1NC(=O)C(O1)C1=CC=CC=C1,Hepatic failure,Human,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Letter 017703/S-011, page:19 PDF 795k",https://www.pharmapendium.com/browse/fda/Pemoline/d8b6acba51936fa943a8d65ce1989b79?reference=19,1996.0,N=C1NC(=O)C(O1)C1=CC=CC=C1
Penicillamine,CC(C)(S)[C@H](N)C(O)=O,Hepatic failure,Human,-0.0,Repeated,Oral,"FDA approval package document: Approval Package 019853/S-014 Part 01, page:14 PDF 1527k",https://www.pharmapendium.com/browse/fda/Penicillamine/8970ba1cdc17c9e4168ef5222da1e1be?reference=14,2004.0,CC(C)(S)[CH](N)C(O)=O
Pioglitazone Hydrochloride,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,Hepatic failure,Human,-1.6532125137753437,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/940059/2011, page:20 PDF 223k",https://www.pharmapendium.com/browse/ema/Pioglitazone Hydrochloride/28737b145f36db81603585b4a73d9fb0?reference=20,2011.0,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Pitavastatin Calcium,O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O,Hepatic failure,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 022363/S-008, S-009 Part 03, page:6 PDF 696k",https://www.pharmapendium.com/browse/fda/Pitavastatin Calcium/ea6bbc31c7abef908790ac73c5f7e399?reference=6,2012.0,O[CH](C[CH](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O
Ponatinib Hydrochloride,CN1CCN(CC1)CC1=C(C=C(NC(=O)C2=CC(C#CC3=CN=C4C=CC=NN34)=C(C)C=C2)C=C1)C(F)(F)F,Hepatic failure,Human,-1.6532125137753437,Repeated,Oral,"FDA approval package document: Label 203469/S-000 Part 02, page:2 PDF 362k",https://www.pharmapendium.com/browse/fda/Ponatinib Hydrochloride/bdf6226473854b0bdb243782179d19d0?reference=2,2012.0,CN1CCN(CC1)CC1=C(C=C(NC(=O)C2=CC(C#CC3=CN=C4C=CC=NN34)=C(C)C=C2)C=C1)C(F)(F)F
Posaconazole,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@@](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1,Hepatic failure,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022003/S-000, page:125 PDF 8671k",https://www.pharmapendium.com/browse/fda/Posaconazole/f5037214d79cab10872dcc1e689683b6?reference=125,2005.0,CC[CH]([CH](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[CH]2CO[C](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1
Pramipexole Dihydrochloride,CCCN[C@H]1CCC2=C(C1)SC(N)=N2,Hepatic failure,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020667 Part 01, page:35 PDF 2068k",https://www.pharmapendium.com/browse/fda/Pramipexole Dihydrochloride/31cc453383ef30ecb800122d88a87894?reference=35,1995.0,CCCN[CH]1CCC2=C(C1)SC(N)=N2
Pravastatin Sodium,[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC([O-])=O)OC(=O)[C@@H](C)CC,Hepatic failure,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 019898/S-062 Part 01, page:21 PDF 1214k",https://www.pharmapendium.com/browse/fda/Pravastatin Sodium/9cd2ea8d0b260d57f67d92089d7b101f?reference=21,2012.0,[H][C]12[CH](C[CH](O)C=C1C=C[CH](C)[CH]2CC[CH](O)C[CH](O)CC([O-])=O)OC(=O)[CH](C)CC
Pregabalin,CC(C)C[C@H](CN)CC(O)=O,Hepatic failure,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: ANNEX I, page:10 PDF 785k",https://www.pharmapendium.com/browse/ema/Pregabalin/98bc1e4bd7201514f285c4f81cb0d53a?reference=10,2021.0,CC(C)C[CH](CN)CC(O)=O
Pseudoephedrine Hydrochloride,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,Hepatic failure,Human,-2.0969100130080562,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021128/S-000, page:17 PDF 1080k",https://www.pharmapendium.com/browse/fda/Pseudoephedrine Hydrochloride/6864d7e491a58e7d1724a7afe12cbc31?reference=17,1999.0,CN[CH](C)[CH](O)C1=CC=CC=C1
Quizartinib Dihydrochloride,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)=NO1,Hepatic failure,Human,-1.7781512503836436,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/CHMP/602286/2019; EMEA/H/C/004468/0000, page:97 PDF 5534k",https://www.pharmapendium.com/browse/ema/Quizartinib Dihydrochloride/e5a1774afc92002d3e3710192a619e0e?reference=97,2019.0,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)=NO1
Raltegravir Potassium,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1,Hepatic failure,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Label 205786/S-000 Part 01, page:10 PDF 342k",https://www.pharmapendium.com/browse/fda/Raltegravir Potassium/e0428acd957bf01f0f639d77e5cdb47a?reference=10,2013.0,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Ramipril,[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,Hepatic failure,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Approval Package 019901/S-046, page:5 PDF 315k",https://www.pharmapendium.com/browse/fda/Ramipril/65423e37e6b2eb8bb13b7fd605ec1be6?reference=5,2005.0,[H][C]12CCC[C]1([H])N([CH](C2)C(O)=O)C(=O)[CH](C)N[CH](CCC1=CC=CC=C1)C(=O)OCC
Ranitidine Hydrochloride,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O,Hepatic failure,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021698/S-000, page:94 PDF 7752k",https://www.pharmapendium.com/browse/fda/Ranitidine Hydrochloride/d649577b6b69cdfb36e83266f39471d9?reference=94,2004.0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O
Regorafenib,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,Hepatic failure,Human,-2.2041199826559246,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 203085/S-000 Part 03, page:2 PDF 387k",https://www.pharmapendium.com/browse/fda/Regorafenib/3cdcf260159befd3ad96758842487521?reference=2,2012.0,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
Rifaximin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C2N=C2C=C(C)C=CN12,Hepatic failure,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022554/S-000 Part 06, page:6 PDF 543k",https://www.pharmapendium.com/browse/fda/Rifaximin/42ecf6c4ada064088a22065b3a8ffcc2?reference=6,2009.0,CO[CH]1\C=C\O[C]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[CH](C)[CH](O)[CH](C)[CH](O)[CH](C)[CH](OC(C)=O)[CH]1C)C1=C2N=C2C=C(C)C=CN12
Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,Hepatic failure,Human,-1.2041199826559248,Repeated,Oral,"FDA approval package document: Approval Package 020272/S-036 Part 02, page:36 PDF 407k",https://www.pharmapendium.com/browse/fda/Risperidone/2a95bb63c1c011ce22ff69a665b3e802?reference=36,2006.0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,Hepatic failure,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020659/S-013; 020680/S-011, page:50 PDF 1907k",https://www.pharmapendium.com/browse/fda/Ritonavir/143054799d45326c3a6bd29a24234e02?reference=50,1998.0,CC(C)[CH](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[CH](C[CH](O)[CH](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Hepatic failure,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022406/S-000 Part 10, page:8 PDF 3770k",https://www.pharmapendium.com/browse/fda/Rivaroxaban/9db0ce0026c9a266144f97525f2bc439?reference=8,2009.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Rofecoxib,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,Hepatic failure,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 021042/S-026; 021052/S-019 Part 01, page:30 PDF 7078k",https://www.pharmapendium.com/browse/fda/Rofecoxib/df9860bde38cd670ee5b5cf92d1a0b45?reference=30,2003.0,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
Rosuvastatin Calcium,CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1,Hepatic failure,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 021366/S-024 Part 01, page:21 PDF 980k",https://www.pharmapendium.com/browse/fda/Rosuvastatin Calcium/2cd0485f9c6ce0b1ebd43dfa3b6b9856?reference=21,2012.0,CC(C)C1=C(\C=C\[CH](O)C[CH](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1
Ruboxistaurin,CN(C)C[C@@H]1CCN2C=C(C3=C2C=CC=C3)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=C2C=CC=C1,Hepatic failure,Human,-1.505149978319906,Repeated,Oral,"EMA approval document: Withdrawal Public Statement EMEA/150964/2007, page:38 PDF 552k",https://www.pharmapendium.com/browse/ema/Ruboxistaurin/80e3fd2450b28d7005fd6f11ddca4cfb?reference=38,2007.0,CN(C)C[CH]1CCN2C=C(C3=C2C=CC=C3)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=C2C=CC=C1
Selexipag,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1,Hepatic failure,Human,-3.2041199826559246,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207947/S-000 Part 05, page:19 PDF 601k",https://www.pharmapendium.com/browse/fda/Selexipag/0a014815d9b037d06801f9864d8abfcb?reference=19,2015.0,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1
Simeprevir Sodium,[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](C[C@@]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C(C)C(OC)=CC=C12)C1=NC(=CS1)C(C)C)C(=O)[N-]S(=O)(=O)C1CC1,Hepatic failure,Human,-2.1760912590556813,Repeated,Oral,"EMA approval document: ANNEX I, page:5 PDF 1173k",https://www.pharmapendium.com/browse/ema/Simeprevir Sodium/af6577bb5777b73b28e830076a8a063f?reference=5,2018.0,[H][C]12C[C]1(NC(=O)[C]1([H])C[CH](C[C]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C(C)C(OC)=CC=C12)C1=NC(=CS1)C(C)C)C(=O)[N-]S(=O)(=O)C1CC1
Simvastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,Hepatic failure,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 019766/S-058 Part 01, page:51 PDF 6839k",https://www.pharmapendium.com/browse/fda/Simvastatin/eec9dab6cfa40cdfdaf5831150afad50?reference=51,2003.0,[H][C]12[CH](C[CH](C)C=C1C=C[CH](C)[CH]2CC[CH]1C[CH](O)CC(=O)O1)OC(=O)C(C)(C)CC
Sirolimus,CO[C@@H]1C[C@@H](CC[C@H]1O)C[C@@H](C)[C@@H]1CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1)OC,Hepatic failure,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/505828/2018; EMEA/H/C/000273, page:2 PDF 102k",https://www.pharmapendium.com/browse/ema/Sirolimus/60520eb12fe9c5d665245b97678a859a?reference=2,2018.0,CO[CH]1C[CH](CC[CH]1O)C[CH](C)[CH]1CC(=O)[CH](C)\C=C(C)\[CH](O)[CH](OC)C(=O)[CH](C)C[CH](C)\C=C\C=C\C=C(C)\[CH](C[CH]2CC[CH](C)[C](O)(O2)C(=O)C(=O)N2CCCC[CH]2C(=O)O1)OC
Stavudine,CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O,Hepatic failure,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020412, page:29 PDF 1683k",https://www.pharmapendium.com/browse/fda/Stavudine/4f5c7cda19621273edb86c06eaf01a9b?reference=29,,CC1=CN([CH]2O[CH](CO)C=C2)C(=O)NC1=O
Strontium Ranelate,[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O,Hepatic failure,Human,-3.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/PRAC/136656/2013, page:27 PDF 2811k",https://www.pharmapendium.com/browse/ema/Strontium Ranelate/bda34774e61b135741ca19f8a9844c5e?reference=27,2013.0,[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O
Sulfasalazine,OC(=O)C1=C(O)C=CC(=C1)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,Hepatic failure,Human,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Label 021243/S-000, page:9 PDF 874k",https://www.pharmapendium.com/browse/fda/Sulfasalazine/cf8a0c6ad016a2a507078cca2fee3df1?reference=9,2000.0,OC(=O)C1=C(O)C=CC(=C1)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
Sunitinib,CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C,Hepatic failure,Human,-1.8750612633917,Repeated,Oral,"EMA approval document: ANNEX I, page:11 PDF 705k",https://www.pharmapendium.com/browse/ema/Sunitinib/95d35eea3df7c71029f241d18fa5927a?reference=11,2021.0,CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C
Tacrine Hydrochloride,NC1=C2C=CC=CC2=NC2=C1CCCC2,Hepatic failure,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 020070/S-001, S-003, S-004, S-006 Part 14, page:56 PDF 9336k",https://www.pharmapendium.com/browse/fda/Tacrine Hydrochloride/5ca35442c7a6262bcfb861e4be5ed2ab?reference=56,1993.0,NC1=C2C=CC=CC2=NC2=C1CCCC2
Tacrolimus,[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@H]1CC[C@@H](O)[C@H](C1)OC,Hepatic failure,Human,-1.4771212547196624,Repeated,Oral,"EMA approval document: ANNEX I, page:13 PDF 402k",https://www.pharmapendium.com/browse/ema/Tacrolimus/e0aadf0d0d9cd73017d274a551b88d47?reference=13,2020.0,[H][C]12O[C](O)([CH](C)C[CH]1OC)C(=O)C(=O)N1CCCC[CH]1C(=O)O[CH]([CH](C)[CH](O)CC(=O)[CH](CC=C)\C=C(C)\C[CH](C)C[CH]2OC)C(\C)=C\[CH]1CC[CH](O)[CH](C1)OC
Telbivudine,CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O,Hepatic failure,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022154/S-000 Part 01, page:75 PDF 6217k",https://www.pharmapendium.com/browse/fda/Telbivudine/fae0e1c84415df1f2cae1dd239c0bc14?reference=75,2009.0,CC1=CN([CH]2C[CH](O)[CH](CO)O2)C(=O)NC1=O
Telithromycin,[H][C@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CN=CC=C1,Hepatic failure,Human,-2.9030899869919438,Repeated,Oral,"EMA approval document: ANNEX I, page:10 PDF 932k",https://www.pharmapendium.com/browse/ema/Telithromycin/0829f6d282c80487372c4bd4505f2337?reference=10,2019.0,[H][C]12[CH](C)C(=O)[CH](C)C[C](C)(OC)[CH](O[CH]3O[CH](C)C[CH]([CH]3O)N(C)C)[CH](C)C(=O)[CH](C)C(=O)O[CH](CC)[C]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CN=CC=C1
Tepotinib Hydrochloride,CN1CCC(CC1)COC1=CN=C(N=C1)C1=CC(CN2N=C(C=CC2=O)C2=CC(=CC=C2)C#N)=CC=C1,Hepatic failure,Human,-2.6532125137753435,Repeated,Oral,"FDA approval package document: Label 214096/S-001, page:5 PDF 394k",https://www.pharmapendium.com/browse/fda/Tepotinib Hydrochloride/e9496daa8c9353b51127caede0c893d5?reference=5,2021.0,CN1CCC(CC1)COC1=CN=C(N=C1)C1=CC(CN2N=C(C=CC2=O)C2=CC(=CC=C2)C#N)=CC=C1
Tetrabenazine,[H][C@@]12CC(=O)[C@@H](CC(C)C)CN1CCC1=CC(OC)=C(OC)C=C21,Hepatic failure,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021894/S-000 Part 01, page:18 PDF 5246k",https://www.pharmapendium.com/browse/fda/Tetrabenazine/57d12081853b7f925c002f53f0c8013e?reference=18,2008.0,[H][C]12CC(=O)[CH](CC(C)C)CN1CCC1=CC(OC)=C(OC)C=C21
Thiotepa,S=P(N1CC1)(N1CC1)N1CC1,Hepatic failure,Human,-0.3010299956639812,Repeated,Intravenous,"EMA approval document: Assessment Report EMEA/H/C/001046, page:55 PDF 672k",https://www.pharmapendium.com/browse/ema/Thiotepa/c1684ffe2ec2ab818791ab1cdf48fbea?reference=55,2009.0,S=P(N1CC1)(N1CC1)N1CC1
Tigecycline,[H][C@@]12CC3=C(C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C,Hepatic failure,Human,-1.6989700043360187,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/CHMP/183367/2011; EMEA/H/C/000644/R/0053, page:20 PDF 465k",https://www.pharmapendium.com/browse/ema/Tigecycline/d3877e43a961ce0aa933fbebe1ad1288?reference=20,2011.0,[H][C]12CC3=C(C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])C2)C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C
Tipranavir,CCC[C@@]1(CCC2=CC=CC=C2)CC(O)=C([C@H](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1,Hepatic failure,Human,-2.6989700043360187,Repeated,Oral,"EMA approval document: Procedural Steps EMA/640381/2020, page:32 PDF 254k",https://www.pharmapendium.com/browse/ema/Tipranavir/ea183337789d9e7d2f278e3607afffe4?reference=32,2020.0,CCC[C]1(CCC2=CC=CC=C2)CC(O)=C([CH](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1
Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,Hepatic failure,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204441/S-000 Part 05, page:16 PDF 600k",https://www.pharmapendium.com/browse/fda/Tolvaptan/26fba97841ed852caa0a9ddc3513d797?reference=16,2013.0,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2
Topiramate,[H][C@@]12OC(C)(C)O[C@]1(COS(N)(=O)=O)OC[C@H]1OC(C)(C)O[C@@H]21,Hepatic failure,Human,-3.0,Repeated,Oral,"FDA approval package document: Label 205122/S-000, page:28 PDF 646k",https://www.pharmapendium.com/browse/fda/Topiramate/eb610a5e72052155b4a084831be75b44?reference=28,2014.0,[H][C]12OC(C)(C)O[C]1(COS(N)(=O)=O)OC[CH]1OC(C)(C)O[CH]21
Tramadol Hydrochloride,COC1=CC(=CC=C1)[C@]1(O)CCCC[C@H]1CN(C)C,Hepatic failure,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021745/S-000 Part 03, page:60 PDF 4029k",https://www.pharmapendium.com/browse/fda/Tramadol Hydrochloride/107fa535995f7af27f787b9c42845eef?reference=60,2007.0,COC1=CC(=CC=C1)[C]1(O)CCCC[CH]1CN(C)C
Ulipristal Acetate,[H][C@@]12CCC3=CC(=O)CCC3=C1[C@H](C[C@@]1(C)[C@@]2([H])CC[C@]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C,Hepatic failure,Human,-1.0,Repeated,Oral,"EMA approval document: Assessment Report EMA/442745/2018; EMEA/H/A-20/1460/C/2041/0043, page:10 PDF 310k",https://www.pharmapendium.com/browse/ema/Ulipristal Acetate/983280aa4e864a17a4652c9ce1ceb851?reference=10,2018.0,[H][C]12CCC3=CC(=O)CCC3=C1[CH](C[C]1(C)[C]2([H])CC[C]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C
Valproic Acid,CCCC(CCC)C(O)=O,Hepatic failure,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 018081/S-001, S-009, S-025; 018082/S-008; 018841/S-008; 005856/S-013; 006800/S-011; 007707/S-004; 008322/S-007 Part 02, page:33 PDF 5153k",https://www.pharmapendium.com/browse/fda/Valproic Acid/c45e2929cad56b2dac1b3a43f96fdf20?reference=33,1978.0,CCCC(CCC)C(O)=O
Venlafaxine Hydrochloride,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,Hepatic failure,Human,-2.3521825181113627,Repeated,Oral,"FDA approval package document: Approval Package 020699/S-045, page:15 PDF 2202k",https://www.pharmapendium.com/browse/fda/Venlafaxine Hydrochloride/18adff0cd53f35b16e09efecc4bf0374?reference=15,2004.0,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
Vigabatrin,NC(CCC(O)=O)C=C,Hepatic failure,Human,-3.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020427/S-000 Part 07, page:68 PDF 6166k",https://www.pharmapendium.com/browse/fda/Vigabatrin/efee566c5d5bc0813df5f24a38b6e661?reference=68,2009.0,NC(CCC(O)=O)C=C
Vitamin E,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(C)C(O)=C(C)C(C)=C2O1,Hepatic failure,Human,-1.3979400086720377,Repeated,Intravenous,Reference from PharmaPendium Published Toxicity: Tocofersolan729   ---   DOI:10.1007/s00228-009-0729-1   JOURNAL:European Journal of Clinical Pharmacology   PAGES:109   VOLUME:66,http://dx.doi.org/10.1007/s00228-009-0729-1,2010.0,CC(C)CCC[CH](C)CCC[CH](C)CCC[C]1(C)CCC2=C(C)C(O)=C(C)C(C)=C2O1
Voriconazole,C[C@@H](C1=C(F)C=NC=N1)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Hepatic failure,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021266/S-000; 021267/S-000 Part 04, page:48 PDF 1582k",https://www.pharmapendium.com/browse/fda/Voriconazole/b91def2fd3ba7fba9e4703146e866659?reference=48,2001.0,C[CH](C1=C(F)C=NC=N1)[C](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F
Zafirlukast,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C,Hepatic failure,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Label 020547/S-029, page:9 PDF 1194k",https://www.pharmapendium.com/browse/fda/Zafirlukast/244ecd1e992ff73be2fed108af9f0eb5?reference=9,2009.0,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C
Zanamivir,[H][C@]1(OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO,Hepatic failure,Human,-2.7781512503836434,Repeated,Intravenous,"EMA approval document: Public Assessment Report EMA/CHMP/851480/2018; EMEA/H/C/004102/0000, page:131 PDF 2375k",https://www.pharmapendium.com/browse/ema/Zanamivir/0160f7132f67bf85b6bfb2d976c2fd6f?reference=131,2019.0,[H][C]1(OC(=C[CH](NC(N)=N)[CH]1NC(C)=O)C(O)=O)[CH](O)[CH](O)CO
Zinc Acetate,CC([O-])=O,Hepatic failure,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: Scientific Discussion, page:25 PDF 431k",https://www.pharmapendium.com/browse/ema/Zinc Acetate/22c77179bea14e7701061bfe5f6fc5e9?reference=25,2004.0,CC([O-])=O
Zonisamide,NS(=O)(=O)CC1=NOC2=CC=CC=C12,Hepatic failure,Human,-2.845098040014257,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020789/S-000 Part 04, page:23 PDF 958k",https://www.pharmapendium.com/browse/fda/Zonisamide/caa2b34dc9fd237046a5b83ba8aa900e?reference=23,1999.0,NS(=O)(=O)CC1=NOC2=CC=CC=C12
